The pharmacological management of treatment-resistant depression: what does the future hold?

References

• Pompili M, Sarli G, Erbuto D, et al. Clinical experiences with intranasal esketamine for major depressive disorder resistant to treatment and with a psychiatric emergency: case presentations. Int Clin Psychopharmacol. 2023;38(3):195–200. doi: 10.1097/YIC.0000000000000455
   PubMed Web of Science ®Google Scholar
• Olgiati P, Serretti A. Persistence of suicidal ideation within acute phase treatment of major depressive disorder: analysis of clinical predictors. Int Clin Psychopharmacol. 2022;37(5):193–200. doi: 10.1097/YIC.0000000000000416
   PubMed Web of Science ®Google Scholar
• Johnston JN, Henter ID, Zarate CA Jr. The antidepressant actions of ketamine and its enantiomers. Pharmacology & Therapeutics. 2023;246:108431. doi: 10.1016/j.pharmthera.2023.108431
   PubMed Web of Science ®Google Scholar
• Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021;384(15):1402–1411. doi: 10.1056/NEJMoa2032994
   PubMed Web of Science ®Google Scholar
• Daws RE, Timmermann C, Giribaldi B, et al. Increased global integration in the brain after psilocybin therapy for depression. Nat Med. 2022;28(4):844–851. doi: 10.1038/s41591-022-01744-z
   PubMed Web of Science ®Google Scholar
• Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49(4):655–663. doi: 10.1017/S0033291718001356
   PubMed Web of Science ®Google Scholar
• Maguire JL, Mennerick S. Neurosteroids: mechanistic considerations and clinical prospects. Neuropsychopharmacol. 2023;Internet. doi: http://dx.doi.org/10.1038/s41386-023-01626-z.
   PubMed Web of Science ®Google Scholar
• Gunduz-Bruce H, Silber C, Kaul I, et al. Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med. 2019;381(10):903–911. doi: 10.1056/NEJMoa1815981
   PubMed Web of Science ®Google Scholar
• Clayton AH, Lasser R, Parikh SV, et al. Zuranolone for the treatment of adults with major depressive disorder: a randomized, placebo-controlled phase 3 Trial. Am J Psychiatry. 2023;180(9):676–684. doi: 10.1176/appi.ajp.20220459
   PubMed Web of Science ®Google Scholar
• Walkery A, Leader LD, Cooke E, et al. Review of allopregnanolone agonist therapy for the treatment of depressive disorders. Drug Des Devel Ther. 2021;15:3017–3026. doi: 10.2147/DDDT.S240856
   PubMed Web of Science ®Google Scholar
• Meshkat S, Teopiz KM, Di Vincenzo JD, et al. Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder. J Affect Disord. 2023;340:893–898. doi: 10.1016/j.jad.2023.08.027
   PubMed Web of Science ®Google Scholar
• Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, et al. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2021;78(9):951–959. doi: 10.1001/jamapsychiatry.2021.1559
   PubMed Web of Science ®Google Scholar
• Albadrani MS, Albadrani MS, Fadlalmola HA, et al. Safety and efficacy of daridorexant in the treatment of insomnia: a systematic review and meta-analysis of randomized controlled trials. Int Clin Psychopharmacol. 2023;38(1):57–65. doi: 10.1097/YIC.0000000000000425
   PubMed Web of Science ®Google Scholar
• Scala M, Fanelli G, De Ronchi D, et al. Clinical specificity profile for novel rapid acting antidepressant drugs. Int Clin Psychopharmacol. 2023;38(5):297–328. doi: 10.1097/YIC.0000000000000488
   PubMed Web of Science ®Google Scholar
• Tabuteau H, Jones A, Anderson A, et al. Effect of AXS-05 (dextromethorphan-bupropion) in major depressive disorder: a randomized Double-blind controlled Trial. Am J Psychiatry. 2022;179(7):490–499. doi: 10.1176/appi.ajp.21080800
   PubMed Web of Science ®Google Scholar
• Iosifescu DV, Jones A, O’Gorman C, et al. Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical Trial (GEMINI). J Clin Psychiatry. 2022;83(4):21m14345. doi: 10.4088/JCP.21m14345
   PubMed Web of Science ®Google Scholar
• Fava M, Stahl S, Pani L, et al. REL-1017 (esmethadone) as adjunctive treatment in patients with major depressive disorder: a phase 2a randomized Double-blind Trial. Am J Psychiatry. 2022;179(2):122–131. doi: 10.1176/appi.ajp.2021.21020197
   PubMed Web of Science ®Google Scholar
• Guidetti C, Serra G, Pani L, et al. REL-1017 (esmethadone) may rapidly reduce dissociative symptoms in adults with major depressive disorder unresponsive to Standard antidepressants: a report of 2 cases. J Clin Psychopharmacol. 2022;42(5):503–506. doi: 10.1097/JCP.0000000000001583
   PubMed Web of Science ®Google Scholar
• Guidetti C, Serra G, Pani L, et al. Subanalysis of subjective cognitive measures from a phase 2, Double-blind, randomized Trial of REL-1017 in patients with major depressive disorder. Prim Care Companion CNS Disord. 2023;25(1):22m03267. doi: 10.4088/PCC.22m03267
   PubMedGoogle Scholar
• Fava M, Stahl SM, De Martin S, et al. Esmethadone-HCl (REL-1017): a promising rapid antidepressant. Eur Arch Psychiatry Clin Neurosci. 2023;273(7):1463–1476. doi: 10.1007/s00406-023-01571-4
   PubMed Web of Science ®Google Scholar
• Serretti A. Psychopharmacology: past, present and future. Int Clin Psychopharmacol. 2022;37(3):82–83. doi: 10.1097/YIC.0000000000000402
   PubMed Web of Science ®Google Scholar
• Benedetti F, Zanardi R, Mazza MG. Antidepressant psychopharmacology: is inflammation a future target? Int Clin Psychopharmacol. 2022;37(3):79–81. doi: 10.1097/YIC.0000000000000403
   PubMed Web of Science ®Google Scholar
• Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry. 2017;4(5):409–418. doi: 10.1016/S2215-0366(17)30015-9
   PubMed Web of Science ®Google Scholar
• Donoso F, Cryan JF, Olavarría-Ramírez L, et al. Inflammation, lifestyle factors, and the microbiome-gut-brain axis: relevance to depression and antidepressant action. Clin Pharmacol Ther. 2023;113(2):246–259. doi: 10.1002/cpt.2581
   PubMed Web of Science ®Google Scholar
• Artigas F, Celada P, Bortolozzi A. Can we increase the speed and efficacy of antidepressant treatments? Part II. Glutamatergic and RNA interference strategies. Eur Neuropsychopharmacol. 2018;28(4):457–482. doi: 10.1016/j.euroneuro.2018.01.005
   PubMed Web of Science ®Google Scholar